Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genprex, Inc. (GNPX)
USD0.64
-0.01 (-2.05%)
US NASDAQ Healthcare Biotechnology
Address
3300 Bee Cave Road 78746
Austin, TX, US
Austin, TX, US
CEO
Ryan Confer
Website
genprex.com
IPO
2018-03-29
CIK 1595248 ISIN US3724463027
Description
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.64
-0.01 (-2.05%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
658.6K
Beta
-0.96
Float Shares
668.2K
Free Float %
40.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.81% | -6.04% | -31.40% | -58.91% | -79.95% | -52.57% | -94.11% | -99.95% | -99.99% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
0.64
DCF (Unlevered)
7.64
+1,092.9%
DCF (Levered)
8.40
+1,211.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-27.65
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+93.5% ★ Q1'26: +95.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-11,821.8% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1,064.2% Q1'26: +2,177.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 15.00M (-100.0%)
|
—
est: 40.00M (-100.0%)
|
—
est: 58.80M (-100.0%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
| EBITDA |
-20.64M
|
-21.10M
|
-15.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-20.66M
|
-21.11M
|
-15.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-20.66M
est: -64.10M (+67.8%)
|
-21.11M
est: -198.21M (+89.3%)
|
-16.23M
est: -58.30M (+72.2%)
|
-53.63M
-53.63M – -53.63M
+8.0% YoY
|
-447.71M
-447.71M – -447.71M
-734.8% YoY
|
-10.07M
-10.07M – -10.07M
+97.8% YoY
|
| SGA |
11.68M
|
10.63M
|
6.09M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-877.50
est: -800.00 (-9.7%)
|
-266.95
est: -212.50 (-25.6%)
|
-17.40
est: -62.50 (+72.2%)
|
-57.50
-57.50 – -57.50
+8.0% YoY
|
-480.00
-480.00 – -480.00
-734.8% YoY
|
-10.80
-10.80 – -10.80
+97.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
9
Total invested
83.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
15
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CVI Investments, Inc. | 3.47M | 5.80% | — | 3.47M | — | 3.47M | CO | Cayman Islands | 2023-07-24 | ↗ |
| 2 | Heights Capital Management, Inc. | 3.47M | 5.80% | — | 3.47M | — | 3.47M | CO | Cayman Islands | 2023-07-24 | ↗ |
| 3 | Christy M. Nance | 3.17M | 20.80% | 3.17M | — | 3.17M | — | IN | USA | 2019-02-15 | ↗ |
| 4 | Loomis, Sayles & Company, L.P. | 2.05M | 5.27% | — | 1.58M | — | 1.58M | IA | Delaware USA | 2019-11-22 | ↗ |
| 5 | Sabby Volatility Warrant Master Fund, Ltd. | 1.91M | 6.84% | — | 1.91M | — | 1.91M | CO | USA | 2020-01-23 | ↗ |
| 6 | Viet-An Hoan Ly | 1.17M | 5.70% | 1.17M | — | 1.17M | — | IN | USA | 2020-02-14 | ↗ |
| 7 | Jack A. Roth | 1.16M | 6.00% | 1.16M | — | 1.16M | 1.16M | IN | USA | 2020-02-19 | ↗ |
| 8 | Hudson Bay Capital Management LP | 1.14M | 7.04% | — | 1.14M | — | — | PN | State of Delaware | 2019-02-01 | ↗ |
| 9 | Sander Gerber | 1.14M | 7.04% | — | 1.14M | — | — | IN | United States | 2019-02-01 | ↗ |
| 10 | Forsakringsaktiebolaget Avanza Pension | 130.6K | 5.00% | 130.6K | — | — | — | FI | Stockholm, Sweden | 2024-10-03 | ↗ |
| 11 | Calamos Market Neutral Income Fund, a series of Calamos Investment Trust | 9.00 | 8.80% | — | 948.9K | — | 948.9K | IV | Cayman Islands | 2020-01-15 | ↗ |
| 12 | MASAYA OTSUKA | — | 6.76% | 175.2K | — | 175.2K | — | IN | JAPAN | 2024-10-22 | ↗ |
| 13 | Daniel B. Asher | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2020-01-31 | ↗ |
| 14 | Intracoastal Capital LLC | — | 0.00% | — | — | — | — | OO | United States of America | 2020-01-31 | ↗ |
| 15 | Mitchell P. Kopin | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2020-01-31 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
9
-11 vs prev Q
New positions
5
Closed positions
16
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ADVISOR GROUP HOLDINGS, INC. | — -8.6K (-100.0%) | — -1.4K (-100.0%) | 0.00% -0.031 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 2 | ALLWORTH FINANCIAL LP | — -125.0 (-100.0%) | — -22.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 3 | BANK OF AMERICA CORP /DE/ | — -715.0 (-100.0%) | — -121.0 (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 4 | BLACKROCK, INC. | — -9.4K (-100.0%) | — -1.6K (-100.0%) | 0.00% -0.034 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 5 | CITIGROUP INC | — -6.1K (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.022 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | — -164.0K (-100.0%) | — -27.8K (-100.0%) | 0.00% -0.594 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 7 | GLOBAL RETIREMENT PARTNERS, LLC | — -5.0 (-100.0%) | — -1.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 8 | GROUP ONE TRADING, L.P. | — -24.0 (-100.0%) | — -4.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 9 | HIGHMARK WEALTH MANAGEMENT LLC | — -500.0 (-100.0%) | — -85.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 10 | JANE STREET GROUP, LLC | — -205.2K (-100.0%) | — -34.8K (-100.0%) | 0.00% -0.744 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 11 | JPMORGAN CHASE & CO | — -5.0 (-100.0%) | — -1.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 12 | MORGAN STANLEY | — -958.0 (-100.0%) | — -162.0 (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 13 | NEMES RUSH GROUP LLC | — -250.0 (-100.0%) | — -42.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -340.1K (-100.0%) | — -57.6K (-100.0%) | 0.00% -1.232 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 15 | TCG ADVISORY SERVICES, LLC | — -17.0K (-100.0%) | — -2.9K (-100.0%) | 0.00% -0.062 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 16 | TOWER RESEARCH CAPITAL LLC (TRC) | — -5.8K (-100.0%) | — -984.0 (-100.0%) | 0.00% -0.021 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 17 | UBS GROUP AG | — -162.2K (-100.0%) | — -27.4K (-100.0%) | 0.00% -0.588 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 18 | VANGUARD GROUP INC | — -433.4K (-100.0%) | — -73.2K (-100.0%) | 0.00% -1.571 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 4.5K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
18.00
Cash buys
—
Cash sales
2.00
Net activity
-18
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | LONGNECKER BRENT M | Director | S-Sale | D | Common Stock | 8 | 1.23 | 9.84 | 9,157 | D | ↗ |
| 2026-02-27 | Confer Ryan M. | Director / Officer | F-InKind | D | Common Stock | 9,330 | 2.00 | 18.7K | 36,331 | D | ↗ |
| 2026-02-27 | Berger Mark Stanley | Officer | F-InKind | D | Common Stock | 7,168 | 2.00 | 14.3K | 21,692 | D | ↗ |
| 2025-12-22 | Wilson William R Jr. | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 9,157 | D | ↗ |
| 2025-12-22 | Moreno Toscano Jose Antonio | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 9,157 | D | ↗ |
| 2025-12-22 | LONGNECKER BRENT M | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 9,165 | D | ↗ |
| 2025-12-22 | Confer Ryan M. | Director / Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 45,661 | D | ↗ |
| 2025-12-22 | Berger Mark Stanley | Officer | A-Award | A | Common Stock | 28,500 | 0.00 | — | 28,860 | D | ↗ |
| 2025-06-30 | Confer Ryan M. | Director / Officer | F-InKind | D | Common Stock | 5,775 | 0.23 | 1.3K | 32,968 | D | ↗ |
| 2025-06-30 | Berger Mark Stanley | Officer | F-InKind | D | Common Stock | 4,500 | 0.23 | 1.0K | 17,971 | D | ↗ |
| 2025-02-18 | Confer Ryan M. | Director / Officer | F-InKind | D | Common Stock | 395 | 0.41 | 161.95 | 38,743 | D | ↗ |
| 2025-02-18 | Berger Mark Stanley | Officer | F-InKind | D | Common Stock | 585 | 0.41 | 239.85 | 22,471 | D | ↗ |
| 2024-12-05 | Wilson William R Jr. | Director | A-Award | A | Common Stock | 4,750 | 0.00 | — | 7,845 | D | ↗ |
| 2024-12-05 | Moreno Toscano Jose Antonio | Director | A-Award | A | Common Stock | 4,750 | 0.00 | — | 7,845 | D | ↗ |
| 2024-12-05 | LONGNECKER BRENT M | Director | A-Award | A | Common Stock | 4,750 | 0.00 | — | 8,220 | D | ↗ |
| 2024-12-05 | Confer Ryan M. | Director / Officer | A-Award | A | Common Stock | 29,375 | 0.00 | — | 39,138 | D | ↗ |
| 2024-12-05 | Berger Mark Stanley | Officer | A-Award | A | Common Stock | 18,250 | 0.00 | — | 23,056 | D | ↗ |
| 2024-02-18 | Varner John Rodney | Director / Officer | F-InKind | D | Common Stock | 2,642 | 4.40 | 11.6K | 26,352 | — | ↗ |
| 2024-02-18 | Confer Ryan M. | Officer | F-InKind | D | Common Stock | 1,126 | 4.40 | 5.0K | 9,763 | — | ↗ |
| 2024-02-18 | Berger Mark Stanley | Officer | F-InKind | D | Common Stock | 1,319 | 4.40 | 5.8K | 4,806 | — | ↗ |
| 2023-06-27 | Wilson William R Jr. | Director | A-Award | A | Common Stock | 123,795 | 0.00 | — | 123,795 | — | ↗ |
| 2023-06-27 | Moreno Toscano Jose Antonio | Director | A-Award | A | Common Stock | 123,795 | 0.00 | — | 123,795 | — | ↗ |
| 2023-06-27 | LONGNECKER BRENT M | Director | A-Award | A | Common Stock | 123,795 | 0.00 | — | 138,795 | — | ↗ |
| 2023-04-21 | Varner John Rodney | Director / Officer | P-Purchase | A | Common Stock | 19,000 | 1.06 | 20.0K | 20,800 | — | ↗ |
| 2023-04-21 | VACZY CATHERINE M | Officer | P-Purchase | A | Common Stock | 20,000 | 1.07 | 21.5K | 265,000 | — | ↗ |
| 2023-02-18 | Varner John Rodney | Director / Officer | A-Award | A | Common Stock | 625,000 | 0.00 | — | 1,159,735 | — | ↗ |
| 2023-02-18 | VACZY CATHERINE M | Officer | A-Award | A | Common Stock | 245,000 | 0.00 | — | 245,000 | — | ↗ |
| 2023-02-18 | Kumar Hermant | Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2023-02-18 | Confer Ryan M. | Officer | A-Award | A | Common Stock | 245,000 | 0.00 | — | 435,499 | — | ↗ |
| 2023-02-18 | Berger Mark Stanley | Officer | A-Award | A | Common Stock | 245,000 | 0.00 | — | 245,000 | — | ↗ |
| 2022-07-28 | Confer Ryan M. | Officer | M-Exempt | A | Common Stock | 116,973 | 0.02 | 1.8K | 190,499 | — | ↗ |
| 2022-06-23 | Wilson William R Jr. | Director | A-Award | A | Stock Option (right to buy) | 83,368 | 1.36 | 113.4K | 83,368 | — | ↗ |
| 2022-06-23 | Moreno Toscano Jose Antonio | Director | A-Award | A | Stock Option (right to buy) | 83,368 | 0.00 | — | 83,368 | — | ↗ |
| 2022-06-23 | LONGNECKER BRENT M | Director | A-Award | A | Stock Option (right to buy) | 83,368 | 1.36 | 113.4K | 83,368 | — | ↗ |
| 2022-06-23 | Kumar Hermant | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-02-04 | Varner John Rodney | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,062,250 | 2.20 | 2.34M | 1,062,250 | — | ↗ |
| 2022-02-04 | VACZY CATHERINE M | Officer | A-Award | A | Stock Option (right to buy) | 325,000 | 2.20 | 715.0K | 325,000 | — | ↗ |
| 2022-02-04 | Kumar Hermant | Officer | A-Award | A | Stock Option (right to buy) | 54,312 | 2.20 | 119.5K | 54,312 | — | ↗ |
| 2022-02-04 | Confer Ryan M. | Officer | A-Award | A | Stock Option (right to buy) | 341,750 | 2.20 | 751.9K | 341,750 | — | ↗ |
| 2022-02-04 | Berger Mark Stanley | Officer | A-Award | A | Stock Option (right to buy) | 98,750 | 2.20 | 217.3K | 98,750 | — | ↗ |
| 2021-12-31 | Varner John Rodney | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 1,800 | — | ↗ |
| 2021-09-27 | Kumar Hermant | Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 2.85 | 1.14M | 400,000 | — | ↗ |
| 2021-09-27 | Berger Mark Stanley | Officer | A-Award | A | Stock Option (right to buy) | 550,000 | 2.85 | 1.57M | 550,000 | — | ↗ |
| 2021-06-24 | Wilson William R Jr. | Director | A-Award | A | Stock Option (right to buy) | 32,376 | 3.55 | 114.9K | 32,376 | — | ↗ |
| 2021-06-24 | Moreno Toscano Jose Antonio | Director | A-Award | A | Stock Option (right to buy) | 32,376 | 3.55 | 114.9K | 32,376 | — | ↗ |
| 2021-06-24 | LONGNECKER BRENT M | Director | A-Award | A | Stock Option (right to buy) | 32,376 | 3.55 | 114.9K | 32,376 | — | ↗ |
| 2021-04-05 | LONGNECKER BRENT M | Director | P-Purchase | A | Common Stock | 15,000 | 4.15 | 62.3K | 15,000 | — | ↗ |
| 2021-03-19 | Varner John Rodney | Director / Officer | A-Award | A | Stock Option (right to buy) | 460,000 | 5.08 | 2.34M | 460,000 | — | ↗ |
| 2021-03-19 | VACZY CATHERINE M | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 5.08 | 1.02M | 200,000 | — | ↗ |
| 2021-03-19 | Redman Michael Thomas | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 5.08 | 1.02M | 200,000 | — | ↗ |
| 2021-03-19 | Confer Ryan M. | Officer | A-Award | A | Stock Option (right to buy) | 235,000 | 5.08 | 1.19M | 235,000 | — | ↗ |
| 2021-03-18 | Wilson William R Jr. | Director | — | D | Stock Option (right to buy) | 11,775 | 2.67 | 31.4K | 0 | — | ↗ |
| 2021-03-18 | Moreno Toscano Jose Antonio | Director | — | D | Stock Option (right to buy) | 11,775 | 2.67 | 31.4K | 0 | — | ↗ |
| 2021-03-18 | LONGNECKER BRENT M | Director | — | D | Stock Option (right to buy) | 11,775 | 2.67 | 31.4K | 0 | — | ↗ |
| 2020-08-21 | Varner John Rodney | Director / Officer | A-Award | A | Stock Option (right to buy) | 530,000 | 3.80 | 2.01M | 530,000 | — | ↗ |
| 2020-08-21 | Confer Ryan M. | Officer | A-Award | A | Stock Option (right to buy) | 270,000 | 3.80 | 1.03M | 270,000 | — | ↗ |
| 2020-07-24 | Wilson William R Jr. | Director | A-Award | A | Stock Option (right to buy) | 42,068 | 3.69 | 155.2K | 42,068 | — | ↗ |
| 2020-07-24 | Moreno Toscano Jose Antonio | Director | A-Award | A | Stock Option (right to buy) | 42,068 | 3.69 | 155.2K | 42,068 | — | ↗ |
| 2020-07-24 | LONGNECKER BRENT M | Director | A-Award | A | Stock Option (right to buy) | 42,068 | 3.69 | 155.2K | 42,068 | — | ↗ |
| 2020-03-18 | LONGNECKER BRENT M | Director | — | — | Common Stock | 0 | 0.00 | — | 20,000 | I | ↗ |
| 2020-03-12 | VACZY CATHERINE M | Officer | — | D | Stock Option (right to buy) | 540,000 | 2.00 | 1.08M | 0 | — | ↗ |
| 2020-03-12 | Redman Michael Thomas | Officer | — | D | Stock Option (right to buy) | 550,000 | 2.00 | 1.10M | 0 | — | ↗ |
| 2019-12-30 | Pearson Robert W. | Director | A-Award | A | Stock Option (Right to Buy) | 67,708 | 0.30 | 20.2K | 67,708 | — | ↗ |
| 2019-12-30 | Friedman David E. | Director | A-Award | A | Stock Option (Right to Buy) | 78,125 | 0.30 | 23.3K | 78,125 | — | ↗ |
| 2019-09-05 | Varner John Rodney | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,800 | 0.89 | 1.6K | 1,800 | — | ↗ |
| 2019-02-12 | BONFIGLIO JOHN N | Director | — | D | Stock Option (right to buy) | 45,976 | 1.45 | 66.7K | 0 | — | ↗ |
| 2019-01-25 | Varner John Rodney | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 615,384 | 1.62 | 996.9K | 615,384 | — | ↗ |
| 2019-01-25 | Pham Julien L | Officer | A-Award | A | Stock Option (Right to Buy) | 432,692 | 1.62 | 701.0K | 432,692 | — | ↗ |
| 2019-01-25 | Confer Ryan M. | Officer | A-Award | A | Stock Option (Right to Buy) | 230,769 | 1.62 | 373.8K | 230,769 | — | ↗ |
| 2018-12-31 | ROTH JACK A | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-11-02 | Varner John Rodney | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 551,284 | 2.15 | 1.19M | 551,284 | — | ↗ |
| 2018-11-02 | Pearson Robert W. | Director | A-Award | A | Stock Option (Right to Buy) | 101,156 | 2.15 | 217.5K | 101,156 | — | ↗ |
| 2018-11-02 | Genprex, Inc. | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 551,284 | 2.15 | 1.19M | 551,284 | — | ↗ |
| 2018-11-02 | Friedman David E. | Director | A-Award | A | Stock Option (Right to Buy) | 101,156 | 2.15 | 217.5K | 101,156 | — | ↗ |
| 2018-09-27 | Ly Viet-An Hoan | 10% Owner | J-Other | D | COMMON STOCK | 475,974 | 0.00 | — | 36,067 | — | ↗ |
| 2018-07-30 | Pham Julien L | Officer | P-Purchase | A | Common Stock | 500 | 3.40 | 1.7K | 500 | — | ↗ |
| 2018-07-27 | Ly Viet-An Hoan | 10% Owner | A-Award | A | Warrant Agreement (right to buy) | 425,000 | 5.00 | 2.13M | 425,000 | — | ↗ |
| 2018-05-23 | Pham Julien L | Officer | A-Award | A | Stock option (right to buy) | 659,346 | 9.80 | 6.46M | 659,346 | — | ↗ |
| 2018-05-23 | Confer Ryan M. | Officer | A-Award | A | Stock option (right to buy) | 327,236 | 9.80 | 3.21M | 327,236 | — | ↗ |
| 2018-03-29 | Varner John Rodney | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 5.00 | 50.0K | 544,735 | — | ↗ |
| 2018-03-29 | ROTH JACK A | 10% Owner | P-Purchase | A | Common Stock | 40,000 | 5.00 | 200.0K | 1,338,999 | — | ↗ |
| 2018-03-29 | Nance Christy M. | 10% Owner | P-Purchase | A | Common Stock | 50,000 | 5.00 | 250.0K | 50,000 | — | ↗ |
| 2018-03-28 | Varner John Rodney | Director / Officer / 10% Owner | — | D | Stock Option (right to buy) | 645,572 | 0.96 | 619.7K | 0 | — | ↗ |
| 2018-03-28 | ROTH JACK A | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,049,853 | — | ↗ |
| 2018-03-28 | Pham Julien L | Officer | — | D | Stock Option (right to buy) | 162,800 | 5.29 | 861.2K | 0 | — | ↗ |
| 2018-03-28 | Pearson Robert W. | Director | — | D | Stock Option (right to buy) | 145,715 | 0.01 | 1.5K | 0 | — | ↗ |
| 2018-03-28 | Nance Christy M. | 10% Owner | — | I | Stock Option (right to buy) | 161,396 | 0.96 | 154.9K | 0 | — | ↗ |
| 2018-03-28 | Ly Viet-An Hoan | 10% Owner | — | D | Stock Option (right to buy) | 56,815 | 0.96 | 54.5K | 0 | — | ↗ |
| 2018-03-28 | Friedman David E. | Director | — | D | Stock Option (right to buy) | 145,715 | 0.01 | 1.5K | 0 | — | ↗ |
| 2018-03-28 | Confer Ryan M. | Officer | — | D | Conmon Stock | 0 | 0.00 | — | 73,526 | — | ↗ |
| 2016-10-01 | Confer Ryan M. | Officer | — | D | Stock option (right to buy) | 86,894 | 5.29 | 459.7K | 0 | — | ↗ |
| 2016-04-11 | Confer Ryan M. | Officer | — | D | Stock option (right to buy) | 161,396 | 0.97 | 155.7K | 0 | — | ↗ |
| 2013-08-01 | Confer Ryan M. | Officer | — | D | Stock option (right to buy) | 116,973 | 0.02 | 1.8K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.63M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Ryan M. Confer President, Chief Executive Officer, and Chief Financial Officer | 480.0K | 96.0K | 90.5K | — | — | 62.4K | 728.9K | 12.41% | ↗ |
| 2 | 2025 | Mark S. Berger Chief Medical Officer | 486.5K | 97.3K | 57.3K | — | — | 47.5K | 688.6K | 8.32% | ↗ |
| 3 | 2024 | Mark S. Berger Chief Medical Officer | 486.5K | — | 19.7K | — | — | 45.5K | 551.7K | 3.57% | ↗ |
| 4 | 2024 | Mark S. Berger Chief Medical Officer | 486.5K | — | 19.7K | — | — | 45.5K | 551.7K | 3.57% | ↗ |
| 5 | 2024 | Ryan M. Confer President, Chief Executive Officer, and Chief Financial Officer | 462.5K | — | 31.7K | — | — | 47.4K | 541.6K | 5.86% | ↗ |
| 6 | 2024 | Ryan M. Confer President, Chief Executive Officer, and Chief Financial Officer | 462.5K | — | 31.7K | — | — | 47.4K | 541.6K | 5.86% | ↗ |
| 7 | 2024 | Catherine M. Vaczy Former Executive Vice President, General Counsel & Chief Strategy Officer | 301.0K | — | — | — | — | 148.1K | 449.1K | 0.00% | ↗ |
| 8 | 2024 | J. Rodney Varner Former President & Chief Executive Officer | 242.5K | — | — | — | — | 12.2K | 254.7K | 0.00% | ↗ |
| 9 | 2023 | J. Rodney Varner President Chief Executive Officer | 583.8K | — | 1.07M | — | — | 28.4K | 1.68M | 63.58% | ↗ |
| 10 | 2023 | J. Rodney Varner Former President & Chief Executive Officer | 583.8K | — | 1.07M | — | — | 28.4K | 1.68M | 63.58% | ↗ |
| 11 | 2023 | Mark S. Berger Chief Medical Officer | 484.2K | — | 419.0K | — | — | 44.0K | 947.1K | 44.23% | ↗ |
| 12 | 2023 | Catherine M. Vaczy Former Executive Vice President, General Counsel Chief Strategy Officer | 478.2K | — | 419.0K | — | — | 36.1K | 933.3K | 44.89% | ↗ |
| 13 | 2023 | Catherine M. Vaczy Former Executive Vice President, General Counsel & Chief Strategy Officer | 478.2K | — | 419.0K | — | — | 36.1K | 933.3K | 44.89% | ↗ |
| 14 | 2023 | Ryan M. Confer President, Chief Executive Officer, and Chief Financial Officer | 425.9K | — | 419.0K | — | — | 41.9K | 886.7K | 47.25% | ↗ |
| 15 | 2022 | J. Rodney Varner President Chief Executive Officer | 557.0K | 282.0K | 1.65M | — | — | 48.0K | 2.53M | 64.97% | ↗ |
| 16 | 2022 | Catherine M. Vaczy Executive Vice President, General Counsel, Chief Strategy Officer | 458.5K | 184.8K | — | 503.4K | — | 61.6K | 1.21M | 41.66% | ↗ |
| 17 | 2022 | Catherine M. Vaczy Former Executive Vice President, General Counsel Chief Strategy Officer | 458.5K | 184.8K | 503.4K | — | — | 61.6K | 1.21M | 41.66% | ↗ |
| 18 | 2022 | Ryan M. Confer Chief Financial Officer | 392.7K | 158.8K | — | 529.4K | — | 55.1K | 1.14M | 46.60% | ↗ |
| 19 | 2022 | Mark S. Berger Chief Medical Officer | 467.2K | 187.1K | 153.0K | — | — | 63.4K | 870.7K | 17.57% | ↗ |
| 20 | 2021 | J. Rodney Varner President Chief Executive Officer | 480.0K | 240.0K | — | 1.60M | — | 27.2K | 2.35M | 68.16% | ↗ |
| 21 | 2021 | Ryan M. Confer Chief Financial Officer | 345.0K | 138.0K | — | 817.3K | — | 39.7K | 1.34M | 60.99% | ↗ |
| 22 | 2021 | Michael T. Redman Former Executive Vice President Chief Operating Officer | 308.5K | — | — | 695.6K | — | 308.1K | 1.31M | 53.01% | ↗ |
| 23 | 2021 | Catherine M. Vaczy Executive Vice President, General Counsel, Chief Strategy Officer | 408.0K | 168.0K | — | 695.6K | — | 21.6K | 1.29M | 53.79% | ↗ |
| 24 | 2020 | J. Rodney Varner President Chief Executive Officer | 487.9K | 240.0K | — | 1.36M | — | 23.0K | 2.11M | 64.48% | ↗ |
| 25 | 2020 | Julien L. Pham Former Chief Operating Officer | 282.7K | — | — | 1.76M | — | 8.3K | 2.06M | 85.84% | ↗ |
| 26 | 2020 | Catherine M. Vaczy Executive Vice President, General Counsel, Chief Strategy Officer | 293.4K | 121.7K | — | 718.2K | — | 159.4K | 1.29M | 55.56% | ↗ |
| 27 | 2020 | Ryan M. Confer Chief Financial Officer | 350.9K | 138.0K | — | 694.3K | — | 33.6K | 1.22M | 57.06% | ↗ |
| 28 | 2020 | Michael T. Redman Former Executive Vice President Chief Operating Officer | 241.2K | 100.0K | — | 731.5K | — | 42.3K | 1.11M | 65.61% | ↗ |
| 29 | 2020 | Catherine M. Vaczy Executive Vice President, General Counsel, Chief Strategy Officer | 293.4K | — | — | 199.5K | — | 159.4K | 773.9K | 25.78% | ↗ |
| 30 | 2019 | Julien L. Pham President and Chief Operating Officer | 375.0K | — | — | 1.58M | — | 14.4K | 1.97M | 80.20% | ↗ |
| 31 | 2019 | Julien L. Pham Former Chief Operating Officer | 375.0K | — | — | 1.58M | — | 14.4K | 1.97M | 80.20% | ↗ |
| 32 | 2019 | Ryan M. Confer Chief Financial Officer | 300.0K | — | — | 662.7K | — | 41.7K | 1.00M | 65.98% | ↗ |
| 33 | 2019 | J. Rodney Varner President Chief Executive Officer | 400.0K | — | — | 229.4K | — | 29.7K | 659.1K | 34.81% | ↗ |
| 34 | 2019 | J. Rodney Varner Chief Executive Officer | 400.0K | — | — | 229.4K | — | 29.7K | 659.1K | 34.81% | ↗ |
| 35 | 2018 | Ryan M. Confer Chief Financial Officer | 225.0K | — | — | 1.15M | — | 13.2K | 1.51M | 76.30% | ↗ |
| 36 | 2018 | J. Rodney Varner Chief Executive Officer | 337.5K | — | — | 953.7K | — | 27.5K | 1.48M | 64.26% | ↗ |
| 37 | 2018 | Julien L. Pham President and Chief Operating Officer | 315.0K | — | — | 109.1K | — | 13.3K | 562.5K | 19.39% | ↗ |
| 38 | 2017 | Ryan M. Confer Chief Financial Officer | 180.0K | — | 388.6K | — | — | 16.5K | 585.1K | 66.42% | ↗ |
| 39 | 2017 | J. Rodney Varner Chief Executive Officer | 300.0K | — | — | — | — | 34.1K | 334.1K | 0.00% | ↗ |
| 40 | 2017 | Julien L. Pham President and Chief Operating Officer | 285.0K | — | — | — | — | 16.5K | 301.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ryan Confer | President, Chief Executive Officer, Chief Financial Officer & Director | 638.4K | male |
| Mark S. Berger | Chief Medical Officer | 631.3K | — |
| Greg Jancarik | Senior Director & Corporate Controller | — | male |
| Jack A. Roth | Chairman of Scientific & Medical Advisory Board | — | — |
| Suzanne Thornton-Jones | Senior Vice President of Regulatory Affairs & Quality | — | — |
| Celina Laney | Chief of Staff | — | female |
| Thomas C. Gallagher | Senior Vice President of Intellectual Property & Licensing | — | male |
| David Schloss | Senior Vice President of Human Resources | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GNPX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
